Payment overview · 2025
General Payments
$925.52
18 reported records · 6 companies
Healthcare provider profile · identity verified
Zachary Riboti, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1316093776
Verified facts
What the public records show
CMS Open Payments records show Zachary Riboti, MD received $925.52 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 46.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $426.64 | 46.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $218.21 | 23.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 13.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $75.04 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.00 | 6.5% | 2 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $20.63 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $920.52 | 17 |
| Education | $5.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $254.77 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $238.84 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.33 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.04 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 144 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
144 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 87 |
| Vascepa | Icosapent Ethyl | 231 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 38 |
| Metformin Hcl | Metformin Hcl | 153 | 32 |
| Linzess | Linaclotide | 144 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 129 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 34 |
| Omeprazole | Omeprazole | 123 | 23 |
| Meloxicam | Meloxicam | 113 | 24 |
| Famotidine | Famotidine | 108 | 25 |
| Lisinopril | Lisinopril | 108 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 18 |
| Furosemide | Furosemide | 100 | 27 |
| Losartan Potassium | Losartan Potassium | 98 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 29 |
| Eliquis | Apixaban | 86 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 23 |
| Januvia | Sitagliptin Phosphate | 71 | 12 |
| Simvastatin | Simvastatin | 70 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 14 |
| Zenpep | Lipase/Protease/Amylase | 67 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 65 | 12 |
| Myrbetriq | Mirabegron | 64 | suppressed |
| Carvedilol | Carvedilol | 59 | suppressed |
| Atenolol | Atenolol | 58 | suppressed |
| Glimepiride | Glimepiride | 56 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 12 |
| Meclizine Hcl | Meclizine Hcl | 54 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 13 |
| Ketoconazole | Ketoconazole | 53 | 14 |
| Azithromycin | Azithromycin | 51 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 17 |
| Repaglinide | Repaglinide | 47 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 45 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 44 | 14 |
| Clotrimazole | Clotrimazole | 44 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 11 |
| Dexilant | Dexlansoprazole | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 42 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Gabapentin | Gabapentin | 37 | 12 |
| Ozempic | Semaglutide | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Creon | Lipase/Protease/Amylase | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Nexium | Esomeprazole Magnesium | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Ranolazine Er | Ranolazine | 32 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Crestor | Rosuvastatin Calcium | 25 | suppressed |
| Cyclosporine | Cyclosporine | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Keppra Xr | Levetiracetam | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $925.52 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, FARXIGA, JARDIANCE, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error